(CercleFinance.com) – The title ends in the green after the raising of the objective of UBS. The analysis office on Thursday raised its price target on the Sanofi title, explaining that it expected ‘double-digit growth’ in net earnings per share (EPS) of the group’s activities this year.
The broker – whose price target goes from 116 to 117 euros – justifies his optimism by the strong growth in the United States of prescriptions for Dupixent, the treatment for atopic dermatitis developed by the laboratory.
According to UBS, sales of the drug could eventually total more than 15 billion euros, against a forecast currently established around 10 billion euros.
According to the broker, Dupixent’s potential could materialize this year with new developments expected from the biopharmaceutical group in the coming months.
UBS maintains a buy recommendation on Sanofi, which it makes one of its preferred stocks (‘top picks’) within European large caps.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
